Sientra, Inc. (NASDAQ:SIEN) developer of medical aesthetics products, is reporting third quarter earnings results on Monday 9th November 2020, after market close.
The consensus estimates from Thomson Reuters are loss of $ 0.36 per share from $ 14.47 million in revenue.
For the full year, analysts predict revenues of $ 61.31 million, while looking forward to loss of $ 1.99 per share.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 94.00 million ~ $ 98.00 million
Click Here For More Historical Outlooks Of Sientra, Inc.
Previous Quarter Performance
Sientra, Inc. posted loss for the second quarter of $ 0.68 per share, from the revenue of $ 12.45 million. According to street consensus, SIEN was expected to report 2Q20 loss of $ 0.43 per share from revenue of $ 8.75 million. The bottom line results missed street analysts by $ 0.25 or 58.14 percent, at the same time, top line results outshined analysts by $ 3.70 million or 42.29 percent.
Stock Performance
On Friday, shares of Sientra, Inc. has traded high as $ 4.47 and has cracked $ 4.31 on the downward trend, reaching $ 4.41 with volume of 306.10 thousand shares.
According to the previous trading day, closing price of $ 4.41, representing a 344.00 % increase from the 52 week low of $ 1.00 and a 54.27 % decrease over the 52 week high of $ 9.71.
The company has a market capital of $ 221.88 million and is part of the Healthcare sector and Medical Instruments & Supplies industry.
Conference Call
Sientra, Inc. will be hosting a conference call at 4:30 PM eastern time on 9th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website sientra.com
Sientra, Inc., a medical aesthetics company, develops and sells medical aesthetics products to plastic surgeons in the United States. It operates through two segments, Breast Products and miraDry. The company offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra, AlloX2, Dermaspan, Softspan, and BIOCORNEUM brand names.
